| 蒋孝华,蔡亚平,李小芬,雷创,刘玲玲,李映菊.熊去氧胆酸治疗慢性乙肝及肝硬化伴胆汁淤积.[J].中南医学科学杂志.,2010,(1):. |
| 熊去氧胆酸治疗慢性乙肝及肝硬化伴胆汁淤积 |
| Ursodeoxycholic Acid on Patients of Chronic Hepatitis B and Hepatitis B Related Cirrhosis With Cholestasis |
| |
| DOI： |
| 中文关键词: 慢性乙型肝炎 肝硬化 胆汁淤积 熊去氧胆酸 |
| 英文关键词:hepatitis B chronic liver cirrhosis cholestasis ursodeoxycholic acid |
| 基金项目: |
| 蒋孝华 蔡亚平 李小芬 雷创 刘玲玲 李映菊 |
| 南华大学第一附属医院感染科;南华大学流行病学教研室; |
| 摘要点击次数: 1164 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的观察熊去氧胆酸(优思弗)治疗慢性乙肝及肝硬化伴胆汁淤积的疗效及安全性。方法将慢性乙肝及肝硬化伴胆汁淤积患者67例随机分为治疗组35例与对照组32例;治疗组在对照组内科治疗基础上加用优思弗胶囊,每次250 mg,每日3次,疗程12周。结果治疗12周后,优思弗治疗组总有效率为85.7%,显著高于对照组的59.4%(P<0.05);谷丙转氨酶(ALT)从145.5±80.4 U/L下降至47.3±35.6 U/L,总胆红素(TBIL)从96.9±37.2μmol/L下降至37.9±37.5μmol/L,直接胆红素(DBIL)从66.4±27.5μmol/L下降至21.9±26.1μmol/L,总胆汁酸(TBA)从78.7±33.1μmol/L下降至27.7±36.0μmol/L,碱性磷酸酶(ALP)从138.1±30.4 U/L下降至76.5±56.5 U/L,γ-谷氨酰转肽酶(γ-GT)从167.0±44.6 U/L下降至84.3±72.8 U/L,与对照组比较差异有统计学意义(P<0.01或P<0.05)。优思弗治疗组不良反应发生率为5.71%(2/35)。结论优思弗治疗慢性乙肝及肝硬化伴胆汁淤积患者有较好... |
| 英文摘要: |
| Objective To assess the efficacy and safty of ursodeoxycholic acid(UDCA)in treatment of chronic hepatitis B and hepatitis B related cirrhosis with intrahepatic cholestasis. Methods Sixty-seven chronic hepatitis B and hepatitis B related cirrhotic patients with cholestasis were randomly divided into the UDCA group(n=35) and the control group(n=32).The UDCA group was given oral capsule of UDCA,250 mg three times daily for 12 weeks besides basic therapy.The control group was only treated with conventional ther... |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|